Novodial

History

2023: Farmsintez bought Novodial

On September 15, 2023, it became known that the manufacturer of drugs "Pharmasintez" Vikram Punia will be engaged in the production of drugs for dialysis. To do this, a deal was concluded to acquire a stake in Novodial LLC.

According to the Kommersant newspaper, the Novodial company was formed in the summer of 2023. Under the terms of the agreement, Pharmasintez receives 70% of this company, while the remaining 30% belongs to Alexei Kataev, general director of the Russian structure of the American supplier of drugs and dialysis equipment Baxter. The financial terms of the transaction were not disclosed.

Pharmasinthesis will be engaged in the production of dialysis drugs

Dialysis is the process of artificially excreting waste products and excess fluid from the body. The procedure is applied when the kidneys are unable to perform their function. The demand for peritoneal dialysis solutions is stable. At the same time, according to estimates, about 65% of such drugs are supplied to the Russian market by Baxter.

The head of DSM Group Sergey Shulyak notes that the organization of the production of solutions for dialysis can cost 2-3 billion rubles. At the same time, Pharmasintez has developed production facilities, and therefore the launch of a new project has good prospects. Filtration systems and solutions for peritoneal dialysis are manufactured for devices of a specific manufacturer. Thus, market participants believe, Novodial will produce products for Baxter equipment.

The Pharmasintez project may be of interest to state customers. Thus, a junior researcher at the Russian National Research Medical University named after N.I. Pirogova Denis Borozdenko notes that the Russian manufacturer will take priority in the procurement of solutions for dialysis within the framework of the state order. Pharmasintese and the Russian representative office of Baxter do not give comments on the project as of mid-September 2023.^[1]

Notes